SCHEMBL29907394

SCHEMBL29907394

O=C(Nc1ccc(C(O)(C(F)F)C(F)F)cc1)c1ccnn(-c2ccccc2OCC(F)(F)F)c1=O

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UGCG Q16739 6/20 0.82
KDM4E B2RXH2 2/20 0.42
AXL P30530 5/20 0.42
MAPT P10636 2/20 0.39
HTT P42858 2/20 0.39
KMT2A Q03164 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39
RAB9A P51151 1/20 0.39
PAX8 Q06710 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
GSK3A P49840 1/20 0.39
EGLN1 Q9GZT9 1/20 0.39
LCLAT1 Q6UWP7 1/20 0.38
MET P08581 3/20 0.38
MERTK Q12866 2/20 0.38
TYRO3 Q06418 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29907352 0.90 UGCG (0.67) UGCGKDM4EAXLLCLAT1MET
SCHEMBL29907426 0.90 UGCG (1.00) UGCGKDM4EAXLMAPTGSK3A
SCHEMBL29907414 0.90 UGCG (0.71) UGCGKDM4EAXLMAPTHTT
SCHEMBL29907634 0.86 UGCG (0.76) UGCGKDM4EAXLGSK3AMET
SCHEMBL29907476 0.84 UGCG (0.81) UGCGKDM4EAXLMAPTHTT
SCHEMBL29907497 0.83 UGCG (0.81) UGCGKDM4EAXLGSK3AMET
SCHEMBL29907392 0.82 UGCG (0.79) UGCGAXLLCLAT1METMERTK
SCHEMBL29907551 0.81 UGCG (0.71) UGCGAXLMETMERTKTYRO3
SCHEMBL29907472 0.81 UGCG (0.79) UGCGAXLGSK3AMETMERTK
SCHEMBL29907547 0.78 UGCG (0.64) UGCGKDM4EMAPTSMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220289679-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220289679-A1 HETEROCYCLIC COMPOUND GBA1, GBA2, GALC UGCG 10/4885KDM4E 2610/4885AXL 4241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.